Mass spectrometry quantitation of P450 isoforms in hepatocytes

Abstract

A method for screening a drug for cytochrome P450 (CYP) induction is provided and can include incubating the drug with a microsome-containing biological sample and then quantitating at least one cytochrome P450 isoform. The isoforms can be selected from 2B6, 3A4, 1A2, and 3A5 isoforms. In some embodiments, the method uses liquid chromatography tandem mass spectrometry (LC-MSMS). A quantitated value can be compared to a threshold value and the drug can be determined to exhibit an acceptable CYP induction potential when the quantitated value does not exceed the threshold value. Isolated peptides are also provided.

Claims

1. A method for determining an amount of a CYP 3A5 isoform of cytochrome P450 (CYP) in a sample, said method comprising spiking into said sample a heavy form of a peptide having a peptide sequence of SEQ ID NO:15, and subjecting said sample to an analysis with a liquid chromatograph tandem mass spectrometer system, said system comprising a triple quadrupole instrument and Multiple Reaction Monitoring (MRM), said analysis comprising detecting at least one isolated peptide of CYP 3A5 having a peptide sequence of SEQ ID NO:15, said analysis is performed by monitoring a precursor-product ion pair transition having an m/z value of about 468/581, 468/679, or 468/736 in said system and processing data from said monitoring to determine said amount.

2. A method for screening a drug for cytochrome P450 (CYP) induction, comprising: incubating the drug with a microsome-containing biological sample; determining a quantitated value of at least one of a CYP 3A5 isoform in said drug incubated with the microsome-containing biological sample, said determining comprising, spiking into said drug incubated with the microsome-containing biological sample, a heavy form of a peptide having SEQ ID NO:15, subjecting said drug incubated with the microsome-containing biological sample to an analysis with a liquid chromatography tandem mass spectrometer system, said system comprising a triple quadrupole instrument and multiple reaction monitoring, said analysis comprising detecting an isolated peptide of said CYP 3A5 isoform, said analysis including monitoring a precursor-product ion pair transition having an m/z value of about 468/581, 468/679, or 468/736 in said system and processing data from said monitoring to determine said quantitated value; comparing the quantitated value to a threshold value; determining that the drug has an acceptable CYP induction potential when the quantitated value does not exceed the threshold value.

Description

BRIEF DESCRIPTION OF THE DRAWINGS

(1) The present teachings will be described with reference to the accompanying drawings. The drawings are intended to illustrate, not limit, the present teachings.

(2) FIG. 1 shows an MRM analysis of 20 g of a microsomal preparation for CYP 1A2, CYP 2B6, and CYP 3A4 (extracted ion chromatogram (XIC) of +MRM (412 pairs)).

(3) FIG. 2 shows an MRM analysis of 1 l of a microsomal preparation for CYP 2B6 (extracted ion chromatogram of +MRM (15 pairs)).

(4) FIG. 3 shows an MRM analysis of 2 g of a microsomal preparation for CYP 1A2 (extracted ion chromatogram of +MRM (57 pairs)).

(5) FIG. 4 shows an MRM analysis of 1 l of a microsomal preparation for CYP 3A4 (extracted ion chromatogram of +MRM (34 pairs)).

(6) FIG. 5A shows an MRM analysis for 30 l of a microsomal preparation for 3A5 (extracted ion chromatogram or +MRM (48 pairs)).

(7) FIG. 5B shows an MRM analysis for 30 l of a microsomal preparation for 3A5 (extracted ion chromatogram of +MRM (48 pairs)).

(8) FIG. 5C shows an MRM analysis for 30 l or a microsomal preparation for 3A5 (extracted ion chromatogram of +MRM (48 pairs)).

(9) FIG. 6 shows a graph showing protein expression changes observed in a hepatocyte sample preparation treated with inducers for CYP 2B6, using RNA assays, enzyme activity assays and the protein quantitation method of the present teachings.

(10) FIG. 7 shows a graph showing protein expression changes observed in a hepatocyte sample preparation treated with inducers for CYP 1A2, using RNA assays, enzyme activity assays and the protein quantitation method of the present teachings.

(11) FIG. 8 shows a graph showing protein expression changes observed in a hepatocyte sample preparation treated with inducers for CYP 3A4, using RNA assays, enzyme activity assays and the protein quantitation method of the present teachings.

DETAILED DESCRIPTION

(12) According to various embodiments, a method for screening a drug for cytochrome P450 (CYP) induction is provided that comprises incubating the drug with a microsome-containing biological sample and quantitating at least one CYP isoform. In some embodiments, the isoforms can comprise one or more isoform selected from 2B6, 3A4, 1A2, and 3A5 isoforms. The method can comprise using a liquid chromatography tandem mass spectrometry (LC-MSMS) technique to quantitate the amount of each isoform. The quantitated value of each can be compared to a threshold value, and the drug can be identified as having an acceptable CYP induction potential when the quantitated value does not exceed the threshold value. The threshold value can be selected or predetermined based on a desired CYP induction potential or based on the CYP induction potential of one or more different drugs, similar or non-similar to the drug being screened. In some embodiments, the microsome-containing biological sample can be derived from a mammal, from a primate, or from a human.

(13) According to various embodiments, the drug can be incubated with a sample containing human hepatocytes. In some embodiments, after incubation with the drug, the sample containing human hepatocytes can be used to obtain at least one microsome fraction by, for example, 16 G centrifugation. The microsome fraction can be analyzed for CYP induction by the drug, by detecting isolated peptides specific to CYP (isoform-specific peptides). According to some embodiments, after incubation with the drug, the sample containing human hepatocytes can be used to obtain at least one S9 fraction by, for example, 9 G centrifugation. The S9 fraction can be analyzed to detect CYP induction by the drug, for example, by detecting isolated peptides specific to CYP (isoform-specific peptides). According to some embodiments, the microsome fraction or the S9 fraction can be analyzed using a liquid chromatography tandem mass spectrometry (LC-MSMS) technique in order to quantitate at least one CYP isoform. The quantitated value of each can be compared to a threshold value, and the drug can be identified as having an acceptable CYP induction potential when the quantitated value does not exceed the threshold value.

(14) According to various embodiments, a method is provided for directly analyzing CYP from hepatocytes. In some embodiments, antibody peptides can be used to pull the isoform-specific peptides directly out of hepatocyctes. According to some embodiments, using antibody peptides to pull the isoform-specific peptides directly out of hepatocytes would have the advantage of not needing to prepare S9 or microsome fractions, and would require less hepatocyte cells for drug incubation.

(15) In some embodiments, the method comprises comparing detected induction to a control. For example, because little or no drug induction of CYPs is desirable, a threshold can be set such that the drug must show less than (<) 40% induction compared to the positive control, to be considered acceptable. In some embodiments, the drug must show less than (<) 30% induction compared to the positive control, to be considered acceptable. In other embodiments, the drug must show less than (<) 20% induction compared to the positive control, to be considered acceptable.

(16) According to various embodiments, a method for determining an amount of at least one isoform of cytochrome P450 (CYP) in a sample, is provided. The method can comprise the use of a mass spectrometry technique, wherein the at least one isoform of cytochrome P450 comprises at least one of CYP 2B6, CYP 3A4, CYP 1A2, and CYP 3A5. The mass spectrometry technique can comprise a tandem mass spectrometry (MSMS) technique and/or a liquid chromatography tandem mass spectrometry (LC-MS/MS) technique. In some embodiments, the technique comprises an LC-MS/MS technique and the use of a triple quadrupole instrument and Multiple Reaction Monitoring (MRM).

(17) FIG. 1 shows a typical MRM analysis for CYP 1A2, CYP 2B6, and CYP 3A4, as well as the housekeeping microsomal proteins (Microsomal GST, Corticosteroid 11 beta, and Microsomal Tryglyceride), from a microsomal sample preparation prepared as described below in the Examples. The quantity of CYP 1A2, CYP 2B6, and CYP 3A4 can be determined by, for example, Isotope Dilution Mass Spectrometry, wherein the sample preparation is spiked with heavy forms of the isoform-specific peptides. The quantity of CYP 1A2, CYP 2B6, and CYP 3A4 can also be determined using other conventional methods known in the art. In some embodiments, the method uses LC-MSMS with multiple reaction monitoring (MRM) quantitation of the isoform-specific peptides and isotope-coded affinity tags (ICAT) to generate a CYP induction profile. The method can use, for example, approaches similar to the approaches presented by Pennington et at to quantitate isoform-specific cysteine-containing peptides labeled with ICAT as described in Proteomics, 6(6), pages 1934-1947 (March 2006), which is incorporated herein in its entirety by reference.

(18) FIG. 2 shows a typical MRM analysis for CYP 2B6 from the microsomal preparation prepared as described herein. Isolated peptides comprising the amino acid sequence of SEQ ID NOS: 1, 2, 3, or 4 identified in Table 1 below are specific to CYP 2B6.

(19) FIG. 3 shows a typical MRM analysis for CYP 1A2 from the microsomal preparation prepared as described herein. The isolated peptides comprising the amino acid sequence of SEQ ID NOS: 8, 9, 10, 11, 12, 13, or 14 identified in Table 3 below are specific to CYP 1A2.

(20) FIG. 4 shows a typical MRM analysis for CYP 3A4 from the microsomal preparation prepared as described herein. The isolated peptides comprising the amino acid sequence of SEQ ID NOs: 5, 6, or 7 identified in Table 2 below are specific to CYP 3A4. It should be understood that peptides comprising the amino acid sequence of SEQ ID NOS: 5, 6, or 7 can also be used to identify and/or quantity CYP 3A3.

(21) The isolated peptides comprising the amino acid sequence of SEQ ID NOs: 15, 16, or 17 identified in Table 4 below are specific to CYP 3A5.

(22) FIGS. 5A-5C show three different panes of a typical MRM analysis for CYP 3A5 from the microsomal preparation prepared as described herein. Each pane relates to specific transitions used for the particular peptide. The isolated peptides comprising the amino acid sequence of SEQ ID NOS: 15, 16, or 17 are specific to CYP 3A5.

(23) According to various embodiments, the method can comprise determining an amount of CYP 2B6 in the sample by detecting an isolated peptide specific to cytochrome P450 (CYP) isoform CYP 2B6, for example, one or more of the isoforms comprising the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3 identified herein. The amount can be deter wined using a triple quadrupole instrument and Multiple Reaction Monitoring (MRM). In some embodiments, the isolated peptide can comprise the amino acid sequence of SEQ ID NO: 1 identified herein, and the method can comprise monitoring precursor-product ion pair transitions having an m/z value of about 548/911, 548/681, or 548/566, wherein the term about as used herein means within a range of +/ one (1) atomic mass unit. In some embodiments, the isolated peptide can comprise the amino acid sequence of SEQ ID NO: 2 identified herein, and the method can comprise monitoring precursor-product ion pair transitions having an m/z value of about 494/777, 494/437, or 494/874. In some embodiments, the isolated peptide can comprise the amino acid sequence of SEQ ID NO: 3 identified herein, and the method can comprise monitoring precursor-product ion pair transitions having an m/z value of about 421/508, 421/607, or 421/694. In some embodiments, the isolated peptide can comprise the amino acid sequence of SEQ ID NO: 4, and the method can comprise monitoring precursor-product ion pair transitions having an m/z value of about 479/499, 479/614, or 479/727.

(24) According to various embodiments, the method can comprise determining an amount of CYP 3A4 in the sample by detecting an isolated peptide specific to cytochrome P450 (CYP) isoform CYP 3A4, comprising the amino acid sequence of SEQ ID NO: 5, SEQ ID NO: 6, or SEQ ID NO: 7 identified herein. The method can use, for example, a triple quadrupole instrument and Multiple Reaction Monitoring (MRM). In some embodiments, the isolated peptide can comprise the amino acid sequence of SEQ ID NO: 5 identified herein, and the method can comprise monitoring precursor-product ion pair transitions having an m/z value of about 440/549, 440/650, or 440/532. In some embodiments, the isolated peptide can comprise the amino acid sequence of SEQ ID NO: 6 identified herein, and the method can comprise monitoring precursor-product ion pair transitions having an m/z value of about 704/794, 704/929, 564/689, 564/745, or 564/790. In some embodiments, the isolated peptide can comprise the amino acid sequence of SEQ ID NO: 7 identified herein, and the method can comprise monitoring precursor-product ion pair transitions having an m/z value of about 798/819, 798/932, or 798/1004.

(25) According to various embodiments, the method can comprise determining an amount of CYP 1A2 in the sample by detecting an isolated peptide specific to cytochrome P450 (CYP) isoform CYP 1A2, comprising the amino acid sequence of SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, or SEQ ID NO: 14, identified herein. The method can use, for example, a triple quadrupole instrument and Multiple Reaction Monitoring (MRM).

(26) In some embodiments, the isolated peptide can comprise the amino acid sequence of SEQ ID NO: 8 identified herein, and the method can comprise monitoring precursor-product ion pair transitions having an m/z value of about 432/636, 432/535, or 432/478. In some embodiments, the isolated peptide can comprise the amino acid sequence of SEQ ID NO: 9 identified herein, and the method can comprise monitoring precursor-product ion pair transitions having an m/z value of about 482/800, 482/628, or 482/743. In some embodiments, the isolated peptide can comprise the amino acid sequence of SEQ ID NO: 10 identified herein, and the method can comprise monitoring precursor-product ion pair transitions having an m/z value of about 491/721, 491/834, or 491/535. In some embodiments, the isolated peptide can comprise the amino acid sequence of SEQ ID NO: 11 identified herein, and the method can comprise monitoring precursor-product ion pair transitions having an m/z value of about 528/501, 528/614, or 528/727. In some embodiments, the isolated peptide can comprise the amino acid sequence of SEQ ID NO: 12 identified herein, and the method can comprise monitoring precursor-product ion pair transitions having an m/z value of about 571/783, 571/971, 571/1028, 381/587, 381/474, or 381/375. In some embodiments, the isolated peptide can comprise the amino acid sequence of SEQ ID NO: 13 identified herein, and the method can comprise monitoring precursor-product ion pair transitions having an m/z value of about 695/695, 695/837, or 695/950. In some embodiments, the isolated peptide can comprise the isolated peptide comprises the amino acid sequence of SEQ ID NO: 14 identified herein, and the method can comprise monitoring precursor-product ion pair transitions having an m/z value of about 536/795, 536/584, or 536/698.

(27) According to various embodiments, the method can comprise determining an amount of CYP 3A5 in the sample by detecting an isolated peptide specific to cytochrome P450 (CYP) isoform CYP 3A5, comprising the amino acid sequence of SEQ ID NO: 15, SEQ ID NO: 16, or SEQ ID NO: 17 identified herein. The method can use, for example, a triple quadrupole instrument and Multiple Reaction Monitoring (MRM). In some embodiments, the isolated peptide can comprise an amino acid sequence of SEQ ID NO: 15 identified herein, and the method can comprise monitoring precursor-product ion pair transitions having an m/z value of about 468/581, 468/679, or 468/736. In some embodiments, the isolated peptide can comprise an amino acid sequence of SEQ ID NO: 16 identified herein, and the method can comprise monitoring precursor-product ion pair transitions baying an m/z value of about 470/494, 470/608, or 470/722. In some embodiments, the isolated peptide can comprise an amino acid sequence of SEQ ID NO: 17 identified herein, and the method can comprise monitoring precursor-product ion pair transitions having an m/z value of about 589/747, 589/696, or 589/647.

(28) According to various embodiments of the present teachings, a kit is provided that can comprise one or more of the isolated peptides specific to one or more of cytochrome P450 (CYP) isoform CYP 2B6, CYP 3A4, CYP 1A2, and CYP 3A5. For example, the kit can comprise one or more isolated proteins specific to CYP 2B6, comprising the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, or SEQ ID NO: 4. The kit can comprise one or more isolated proteins specific to CYP isoform CYP 3A4, comprising the amino acid sequence of SEQ ID NO: 5, SEQ ID NO: 6, or SEQ ID NO: 7. The kit can comprise one or more isolated proteins specific to CYP isoform CYP 1A2, comprising the amino acid sequence of SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10. SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, or SEQ ID NO: 14. The kit can comprise one or more isolated proteins specific to CYP isoform CYP 3A5, comprising the amino acid sequence of SEQ ID NO: 15, SEQ ID NO: 16, or SEQ ID NO: 17.

(29) In some embodiments, the kit can comprise at least one isolated peptide specific to each of CYP isoforms CYP 2B6, CYP 3A4, CYP 1A2, and CYP 3A5. For example, the kit can comprise each of the isolated peptides of SEQ ID NOS: 1-17 identified herein, and further can comprise instructions for measuring Q1 and Q3 transition values for each of the isoform-specific peptides. The kit can comprise enzyme digestion components including buffers and enzymes, other buffers, and optionally other reagents and/or components. In some embodiments, the kit can comprise, for example, a homogeneous assay such that the user need only add a sample. In some embodiments, the kit can comprise calibration or normalization reagents or standards. Information pertaining to instrument settings that can or should be used to perform an assay can also be included in the kit. Information pertaining to sample preparation, operating conditions, volumetric amounts, temperature settings, and the like, can be included with the kit.

(30) According to various embodiments, different transitions can be used to measure and benchmark assay results, depending on various factors. Accordingly, the kit can comprise different transition values and/or suggested settings, useful to make comparative measurements between a sample and one or more control reagents. The kit can include instructions to measure specific pairs of transition values, for example, the Q1/Q3 transition pair, or the values of one or more different transition pairs.

(31) The kit can be packaged in a hermetically sealed container containing one or more regent vessels and appropriate instructions. An electronic medium can be included in the kit, having stored thereon electronic information pertaining to one or more assays, measurement values, transition pairs, operating instructions, software for carrying out operations, a combination thereof, or the like.

EXAMPLES

(32) The present teachings can be even more fully understood with reference to the examples and =tilting data that follow. In the examples below and the results shown in the attached drawing figures, a CYP induction study was undertaken as follows.

(33) Hepatocyte Treatment

(34) Primary cultures of human hepatocytes were treated for 72 hours with the prototypical liver enzyme inducers 3-methylcholanthrene (3-MC, 2 M), phenobarbital (PB, 1 mM), or rifampicin (RIF, 10 M) to enhance the expression and activity of CYP1A2, CYP2B6, and CYP3A4, respectively. The CYP quantitation method of the present teachings was used to determine the amount of CYP in the sample after treatment with the liver enzyme inducers. In addition, CYP activity was measured by metabolite formation from selective substrates (phenacetin, bupropion and testosterone, respectively) and mRNA was measured by qRT-PCR (Taqman, Applied Biosystems).

(35) Microsome Preparation

(36) Microsomal subcellular fractions were prepared by lysing treated hepatocytes in homogenization buffer (50 mM TRIS-HCl, pH 7.0, 150 mM KCl, 2 mM EDTA) followed by centrifugation at 9,000g for 20 minutes at 4 C. The supernatant (S9 fraction) was then spun at 100,000g for 60 minutes at 4 C. The resulting microsomal pellet was resuspended in 0.25 M sucrose and stored at 80 C. until analysis.

(37) Tryptic Digestion

(38) To 100 l of each microsomal preparation, 5 l of 2% SDS was added, followed by 10 l of 50 mM TCEP and incubated at 60 C. for 1 hr. 5 l of 0.1M MMTS was added and incubated at room temperature for 10 minutes. 100 l of 100 mM TRIS (pH=8.50) was then added followed by 50 g of trypsin and the resultant solution was digested overnight at 37 C. One (1) ng of each isotopically enriched synthetic peptide was added to the digest and analyzed by LC-MS.

(39) Chromatography

(40) Chromatography was performed using an Agilent 1100 system (Agilent of Santa Clara, Calif.) coupled to a C18 Jupiter Proteo 502.0 mm column (Phenomenex of Torrance, Calif.). The gradient was 5-40% B over 15 minutes with A consisting of 2% ACN, 0.1% formic and B consisting of 90% ACN, 10% H2O, 0.1% formic acid. Flow rate was 700 L/min.

(41) Mass Spectrometry

(42) Samples were analyzed on a Applied Biosystems MDS SCIEX 4000 QTRAP LC/MS/MS system, using a Turbo V source and Analyst 1.5. For quantitation, scheduled MRM (sMRM) was used to maximize dwell time on each transition.

(43) Data Processing

(44) Quantitative data was processed using MultiQuant 1.2 software available from Applied Biosystems, LLC of Foster City, Calif.

(45) Results

(46) FIG. 6 is a graph comparing the changes in expression of CYP 2B6 observed using the RNA assay, the CYP activity assay (designated enzyme activity assay in the figures), and a CYP quantitation method of the present teachings (designated protein assay in the figures). The 3-MC is a vehicle control and induces basal levels of CYP 2B6. The PB is a prototypical inducer for CYP 2B6, by CAR nuclear receptor activation. The RIF is also a known inducer of CYP 2B6. As is shown, protein expression changes observed in the CYP activity assay and RNA assay generally mirror the expression changes observed using a CYP quantitation method of the present teachings.

(47) FIG. 7 is a graph comparing the changes in expression of CYP 1A2 observed using the RNA assay, the CYP activity assay (designated enzyme activity assay in the figures), and the CYP quantitation method of the present teachings (designated protein assay in the figures). The 3-MC is a prototypical inducer of CYP 1A2 by AhR nuclear receptor activation. The PB and RIP are vehicle controls inducing basal levels of 1A2, if any. As is shown, protein expression changes observed in the CYP activity assay and RNA assay generally mirror the expression changes observed using a CYP quantitation method of the present teachings, except that the RNA assay for the sample created with 3MC exhibits very high levels of RNA. The RNA assay cannot accurately quantify proteins because not all mRNA is converted to protein.

(48) FIG. 8 is a graph comparing the changes in expression of CYP 3A4 observed using the RNA assay, the CYP activity assay (designated enzyme activity assay in the figures), and a CYP quantitation method of the present teachings (designated protein assay in the figures). The 3-MC minimally induces CYP 3A4. The PB significantly induces 3A4. The RIF is a prototypical inducer of CYP 3A4 by PXR nuclear receptor activation. As is shown, protein expression changes observed in the CYP activity assay and RNA assay generally mirror the expression changes observed using the CYP quantitation method of the present teachings.

(49) Table 1 below shows sequences of the peptides determined, according to the present teachings, to be specific to cytochrome P450 (CYP) isoform CYP 2B6, along with their optimal MRM Q1, Q3 transitions. According to various embodiments, these observed peptides and transitions can be used to enable a reliable CYP quantitation of the isoform CYP 2B6.

(50) TABLE-US-00001 TABLE1 2B6Human Q1 Q3 IAMVDPFFR 548.3 911.4 (SEQIDNO:1) 548.3 681.3 548.3 566.3 IPPTYQIR 494.3 777.4 (SEQIDNO:2) 494.3 437.7 494.3 874.5 FSVTTMR 421.2 508.4 (SEQIDNO:3) 421.2 607.3 421.2 694.4 ETLDPSAPK 479.2 499.3 (SEQIDNO:4) 479.2 614.3 479.2 727.4

(51) Table 2 below shows sequences of the peptides determined, according to the present teachings, to be specific to cytochrome P450 (CYP) isoform CYP 3A4, along with their optimal MRM Q1, Q3 transitions. According to various embodiments, these observed peptides and transitions can be used to enable a reliable CYP quantitation of the isoform CYP 3A4.

(52) TABLE-US-00002 TABLE2 3A4Human Q1 Q3 EVTNFLR 439.7 549.3 (SEQIDNO:5) 439.7 650.5 439.7 532.3 LSLGGLLQPEKPVVLK 704.4 794.5 (SEQIDNO:6) 704.4 929.8 LSLGGLLQPEKPVVLK+ 3 564.3 789.5 (SEQIDNO:6) 564.3 745.9 564.3 689.4 VWGFYDGQQPVLAITDPDMIK 798.4 819.4 (SEQIDNO:7) 798.4 932.5 798.4 1003.5

(53) Table 3 below shows sequences of the peptides determined, according to the present teachings, to be specific to cytochrome P450 (CYP) isoform CYP 1A2, along with the optimal MRM Q1, Q3 transitions. According to various embodiments, these observed peptides and transitions can be used to enable a reliable CYP quantitation of the isoform CYP 1A2.

(54) TABLE-US-00003 TABLE3 1A2Human Q1 Q3 DITGALFK 432.7 636.4 (SEQIDNO:8) 432.7 535.3 432.7 478.3 YGDVLQIR 482.3 800.5 (SEQIDNO:9) 482.3 628.4 482.3 743.4 FLWFLQK 491.3 721.4 (SEQIDNO:10) 491.3 834.4 491.3 535.3 ASGNLIPQEK 528.7 501.2 (SEQIDNO:11) 528.7 614.4 528.7 727.4 IGSTPVLVLSR+ 2 571.4 783.5 (SEQIDNO:12) 571.4 971.6 571.4 1028.6 IGSTPVLVLSR+ 3 381.1 587.4 (SEQIDNO:12) 381.1 474.3 381.1 375.2 SPPEPWGWPLLGHVLYGK 695.4 695.9 (SEQIDNO:13) 695.4 837.5 695.4 950.5 YLPNPALQR 536.3 795.4 (SEQIDNO:14) 536.3 584.3 536.3 698.4

(55) 10050 Table 4 below shows sequences of the peptides determined, according to the present teachings, to be specific to cytochrome P450 (CYP) isoform CYP 3A5, along with their optimal MRM Q1, Q3 transitions. According to various embodiments, these observed peptides and transitions can be used to enable a reliable CYP quantitation of the isoform CYP 3A5.

(56) TABLE-US-00004 TABLE4 3A5 Q1 Q3 SLGPVGFMK 468.5 581.5 (SEQIDNO:15) 468.5 678.1 468.5 735.5 DTINFLSK 469.5 494.3 (SEQIDNO:16) 469.5 608.4 469.5 721.5 GSMVVIPTYALHHDPK 589.2 746.5 (SEQIDNO:17) 589.2 696 589.2 646.5

(57) Table 5 below shows sequences of the peptides along with their optimal MRM Q1, Q3 transitions for the house-keeping microsomal protein Microsomal GST. According to various embodiments, the concentration of this observed peptide is unaffected by drug incubation and thus the peptide can be useful as a normalization protein to enable reliable CYP quantitation.

(58) TABLE-US-00005 TABLE5 MicrosomalGST Q1 Q3 DVNVENVNQQR 657.8 758.3 (SEQIDNO:18) 657.8 887.5 657.8 545.3 MYLLALK 426.3 720.5 (SEQIDNO:19) 426.3 557.4 426.3 444.3 NALLPEGIPSLLK 682.9 1066.7 (SEQIDNO:20) 682.9 727.5 682.9 953.6

(59) Table 6 below shows sequences of the peptides along with their optimal MRM Q1, Q3 transitions for the house-keeping microsomal protein Microsomal Triglyceride. According to various embodiments, the concentration of this observed peptide is unaffected by drug incubation and thus the peptide can be useful as a normalization protein to enable reliable CYP quantitation.

(60) TABLE-US-00006 TABLE6 MicrosomalTriglyceride Q1 Q3 MMLMSTATAFYR 711.8 829.4 (SEQIDNO:21) 711.8 916.2 711.8 1047.5

(61) Table 7 below shows sequences of the peptides along with their optimal MRM Q1, Q3 transitions for the house-keeping microsomal protein Corticosteroid 11 beta. It should be understood that the Q1 and Q3 masses for the peptide of SEQ ID NO: 22 in Table 7 refers to the MMTS alkylated peptide and that changing to a different alkylating reagent will change the Q1, Q3 masses. In addition, alkylating reagents other than MMTS can be used. According to various embodiments, the concentration of this observed peptide is unaffected by drug incubation and thus the peptide can be useful as a normalization protein to enable reliable CYP quantitation.

(62) TABLE-US-00007 TABLE7 Corticosteroid11beta Q1 Q3 EECALEIIK 547.3 615.4 (SEQIDNO:22) 547.3 686.4 547.3 835.4 FALDGFFSSIR 630.3 928.4 (SEQIDNO:23) 630.3 1041.5 630.3 813.4

(63) The observed isoform-specific tryptic peptides that are detected using LC-MSMS analysis of microsomes, along with their optimal Q1, Q3 transitions, enable a method for CYP quantitation of the isoforms 1A2, 2B6, 3A4, and 3A5 without the need for any chemical labeling approaches.

(64) Other embodiments of the present teachings will be apparent to those skilled in the art from consideration of the present specification and practice of the present teachings disclosed herein. It is intended that the present specification and examples be considered as exemplary only.